This 1b randomized double blind placebo controlled clinical trial evaluates the safety and immunogenicity of the vaccine regimen ALVAC-HIV (vCP1521) followed by
AIDSVAX? B/E in healthy, HIV-1 uninfected adult participants in South Africa. The study further attempts to elucidate immune responses to the HIV vaccine regimen, by
comparing them to immune responses elicited by licensed tetanus or hepatitis B vaccines.